Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
devimistat + docetaxel
- Development stage
- Unknown
- Lead developer
- Cornerstone
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Devimistat (CPI-613) in combination with docetaxel is an investigational therapeutic regimen studied for the treatment of advanced non-small cell lung cancer (NSCLC). Devimistat is a first-in-class small molecule lipoate analog that targets the mitochondrial tricarboxylic acid (TCA) cycle. It selectively inhibits pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KGDH) in cancer cells, leading to mitochondrial stress and increased sensitivity to cytotoxic agents. Docetaxel is a microtubule-stabilizing taxane that induces cell cycle arrest and apoptosis. This combination was evaluated in a Phase I/II clinical trial led by Wake Forest University Health Sciences to determine safety and efficacy in patients with Stage IIIB/IV NSCLC who had failed prior therapy.
- Brand names
- Taxotere
- Other names
- 6,8-bis(benzylthio)octanoic acid + docetaxel
02
Targets
α-KGDH (Alpha-ketoglutarate dehydrogenase complex)PDH (Pyruvate dehydrogenase complex)BCL2L1 (B-cell lymphoma-extra large protein)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on devimistat + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on devimistat + docetaxel.